NUS Links:
Gold nanoparticles (NPs) are promising for cancer therapy due to their versatile properties. However, their interactions with cells vary, affecting reproducibility and application. To optimise this, Dr Andy Tay Kah
CIITA is the master regulator of MHC class-II immune genes that are important for defense mechanism against infections and cancer development. CIITA is controlled by three specific switches used in
Chemotherapy, although the first line of defense in cancer treatment, is indiscriminate and is damaging to the entire body, which, ironically, worsens a patient’s chances of getting better from cancer.
This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the first author, investigates the role of extracellular vesicles (EVs) in
Detecting cancer-driving mutations is crucial for understanding cancer and developing treatments. Existing prediction tools vary in accuracy. N2CR member A/Prof Chen Ee Sin co-led the study on DriverDetect, a machine
Led by N2CR member A/Prof Polly Chen, this research highlights the crucial role of ‘death associated protein 3’ (DAP3) in regulating N6-methyladenosine (m6A) RNA methylation, a process often disrupted in
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) is challenging to treat. Outcome for such patients is dismal. A recent experimental treatment – using CD7 CAR T-cell therapy, developed by N2CR member
A recent phase l trial evaluated the safety and efficacy of combining pressurised intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) with nivolumab in patients with gastric cancer peritoneal metastases (GCPM). Eighteen patients from
A breakthrough study, co-led by N2CR member A/Prof Raghav Sundar and includes Prof Jimmy So, A/Prof Yvonne Tay and Dr Yong Wei Peng, has provided new hope for gastric cancer
Multiple myeloma is a cancer of plasma cells, and its development and therapy resistance remain poorly understood. This study led by N2CR members, Prof Chng Wee Joo and Dr Zhou